AI assistant
Sending…
Design Therapeutics, Inc. — Director's Dealing 2021
Mar 26, 2021
33059_dirs_2021-03-25_cd82f0af-b570-4943-9c9f-1c95afe3cb2a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-03-25
Reporting Person: Siffert Joao MD (Director, President and CEO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 122699 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $0.95 | 2030-10-28 | Common Stock (644171) | Direct |
More from Design Therapeutics, Inc.
Regulatory Filings
2026
May 18
Proxy Solicitation & Information Statement
2026
Apr 23
Annual Report
2026
Apr 23
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Feb 17
Regulatory Filings
2026
Jan 30
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5